Gilead Sciences Inc. (NASDAQ:GILD) received a $90.00 price objective from stock analysts at Evercore ISI in a note issued to investors on Saturday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Evercore ISI’s price target would suggest a potential upside of 23.71% from the company’s previous close.

Several other equities research analysts have also issued reports on the stock. Jefferies Group boosted their price target on shares of Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday, October 5th. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $108.00 target price on shares of Gilead Sciences in a report on Monday, August 15th. Berenberg Bank assumed coverage on shares of Gilead Sciences in a report on Thursday, September 22nd. They issued a “buy” rating on the stock. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Sunday, July 10th. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 6th. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average price target of $103.60.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) traded up 0.23% during mid-day trading on Friday, hitting $72.92. 5,447,867 shares of the company were exchanged. Gilead Sciences has a 12-month low of $72.21 and a 12-month high of $111.11. The company has a 50 day moving average of $77.93 and a 200 day moving average of $84.45. The stock has a market cap of $96.23 billion, a P/E ratio of 6.40 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.15 EPS. On average, equities research analysts expect that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.

In other news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the completion of the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at $250,829,982.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John F. Milligan sold 70,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total value of $5,441,800.00. Following the sale, the insider now directly owns 1,128,963 shares of the company’s stock, valued at approximately $87,765,583.62. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several large investors have recently bought and sold shares of GILD. Bank of Montreal Can bought a new position in Gilead Sciences during the second quarter worth approximately $427,750,000. Capital World Investors increased its position in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares during the period. Investec Asset Management LTD bought a new position in Gilead Sciences during the first quarter worth approximately $280,342,000. Parnassus Investments CA increased its position in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares during the period. Finally, NN Investment Partners Holdings N.V. bought a new position in Gilead Sciences during the first quarter worth approximately $180,268,000. 78.00% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.